Kristy Kuplast‐Barr

PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity

Joseph M. Gozgit, Melissa M. Vasbinder, Ryan Abo et al. · Cancer Cell · 2021 · 171 citations

Cytokine, Cancer Immunosurveillance, Medicine +9

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: <i>In Vitro</i> and <i>In Vivo</i> Preclinical Models

Elayne Chan-Penebre, Kelli Armstrong, Allison E. Drew et al. · Molecular Cancer Therapeutics · 2017 · 163 citations

A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants

Laurie B. Schenkel, Jennifer R. Molina, Kerren K. Swinger et al. · Cell chemical biology · 2021 · 71 citations · Full text

Inflammation, Selective Parp14 Inhibitor, Inflammatory Responses +10

Targeted Degradation of PARP14 Using a Heterobifunctional Small Molecule

Tim J. Wigle, Yue Ren, Jennifer R. Molina et al. · ChemBioChem · 2021 · 23 citations

A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.

Gerald S. Falchook, Manish R. Patel, Timothy A. Yap et al. · Journal of Clinical Oncology · 2021 · 16 citations

Chemoprevention Strategy, Immunology, Pathology +17